Celyad Oncology SA (CYAD) Stock Analyst Ratings
USA - NASDAQ:CYAD - US1512052002 - ADR
0.47 USD
-0.06 (-11.1%)
ChartMill assigns a Buy % Consensus number of 40% to CYAD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.48. This target is 1.41% above the current price.
CYAD was analyzed by 10 analysts. The buy percentage consensus is at 40. So analysts seem to be rather negative about CYAD.
In the previous month the buy percentage consensus was at a similar level.
CYAD was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-01-11 | Wells Fargo | Maintains | Overweight |
Celyad Oncology SA / CYAD FAQ
What is the average price target for Celyad Oncology SA (CYAD) stock?
10 analysts have analysed CYAD and the average price target is 0.48 USD. This implies a price increase of 1.41% is expected in the next year compared to the current price of 0.47.
What is the consensus rating for Celyad Oncology SA (CYAD) stock?
The consensus rating for Celyad Oncology SA (CYAD) is 40 / 100 . This indicates that analysts generally have a neutral outlook on the stock.